At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 52 enrolled
Drug / intervention
Pembrolizumab 200 mg Q3Wdrug
Likely dose
Pembrolizumab 200 mg Q3Wfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluating Immune Checkpoint Inhibition In Solid Tumor Patients With Homologous Recombination Repair Deficiency
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab 200 mg Q3W for Solid Tumor, Adult. Completed, enrolled 52 participants across 1 site.
Detailed Summary
Phase II trial in which patients with metastatic solid tumors experiencing progression after first line standard chemotherapy or for which there is no standard chemotherapy, and for which pembrolizumab does not have an FDA or compendia listing approved indication, will receive pembrolizumab intravenously at a dose of 200 mg every 3 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Adult
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC, Miami Cancer Institute
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 2017
Enrollment StartNov 2017
Primary CompletionOct 2020
Study CompletionMar 2022
TodayJul 2026
First PostedSep 7, 2017
Enrollment StartNov 3, 2017
Primary CompletionOct 20, 2020
Study CompletionMar 19, 2022
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 8.8 years ago
Interventions
Pembrolizumab 200 mg Q3Wdrug
Pembrolizumab 200 mg Intravenous Infusion every 3 weeks administered on Day 1 of each 3 week cycle